Endogenously synthesized cholesterol accounts for roughly 10% of total body cholesterol. Most of this synthesis occurs in the cytoplasm of liver cells. Acetyl-CoA functions as the substrate for the initiation of cholesterol synthesis.
In the first step of cholesterol synthesis, two acetyl-CoA molecules are condensed into a single acetoacetyl-CoA molecule.
The cytosolic isoenzyme of HMG-CoA synthase will add an additional acetyl-CoA molecule to acetoacetyl-CoA, forming HMG-CoA. It is important to note that this isoenzyme of HMG-CoA synthase is located in the cytoplasm, whereas the HMG-CoA synthase enzyme that plays a role in ketogenesis is located in the mitochondria.
HMG-CoA is a molecule formed from three acetyl-CoA molecules (one acetyl-CoA and one acetoacetyl-CoA) in the cytoplasm of hepatocytes. This molecule is an intermediate in cholesterol synthesis as well as ketogenesis.
HMG-CoA reductase catalyzes the rate-limiting step of cholesterol synthesis. This enzyme forms mevalonate from HMG-CoA. This enzyme’s activity is upregulated by insulin and thyroxine, whereas its activity is downregulated by glucagon and catecholamines. Statins work by inhibiting this enzyme.
Mevalonate is synthesized from HMG-CoA by HMG-CoA reductase. This is the rate-limiting step in cholesterol synthesis, and is irreversible.
In the final phase of cholesterol synthesis, mevalonate undergoes a multi-step process to finally form cholesterol. This resulting cholesterol can be used for steroid synthesis, stabilization of cellular membranes, or as a precursor to vitamin D.
Picmonic's rapid review multiple-choice quiz allows you to assess your knowledge.
*Average video play time: 2-3 minutes
Unforgettable characters with concise but impactful videos (2-4 min each)